Literature DB >> 29123946

Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage.

Hiromi Takaki1, Hiroaki Shime1, Misako Matsumoto1, Tsukasa Seya1.   

Abstract

Poly(I:C) acts on dendritic cells to induce potent antitumor effects through the production of cytokines/interferons, activation of natural killer cells and proliferation of cytotoxic T lymphocytes. In some tumor or myeloid lineages, poly(I:C) seemed to induce necroptosis in concert with a pan-caspase inhibitor by directly acting on toll-like receptor (TLR) 3 in both in vivo and in vitro models.

Entities:  

Keywords:  Interferon; TLR3/TICAM-1 pathway; necroptosis; viral RNA

Year:  2015        PMID： 29123946      PMCID： PMC5665066          DOI： 10.1080/2162402X.2015.1078968

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.

Authors:  Hiroaki Shime; Misako Matsumoto; Hiroyuki Oshiumi; Shinya Tanaka; Akio Nakane; Yoichiro Iwakura; Hideaki Tahara; Norimitsu Inoue; Tsukasa Seya
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-19       Impact factor: 11.205

2.  Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo.

Authors:  Misako Matsumoto; Megumi Tatematsu; Fumiko Nishikawa; Masahiro Azuma; Noriko Ishii; Akiko Morii-Sakai; Hiroaki Shime; Tsukasa Seya
Journal:  Nat Commun       Date:  2015-02-18       Impact factor: 14.919

3.  PolyI:C-Induced, TLR3/RIP3-Dependent Necroptosis Backs Up Immune Effector-Mediated Tumor Elimination In Vivo.

Authors:  Ryo Takemura; Hiromi Takaki; Seiji Okada; Hiroaki Shime; Takashi Akazawa; Hiroyuki Oshiumi; Misako Matsumoto; Takanori Teshima; Tsukasa Seya
Journal:  Cancer Immunol Res       Date:  2015-04-21       Impact factor: 11.151

4.  Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation.

Authors:  Takashi Ebihara; Masahiro Azuma; Hiroyuki Oshiumi; Jun Kasamatsu; Kazuya Iwabuchi; Kenji Matsumoto; Hirohisa Saito; Tadatsugu Taniguchi; Misako Matsumoto; Tsukasa Seya
Journal:  J Exp Med       Date:  2010-11-08       Impact factor: 14.307

5.  Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models.

Authors:  Hiroaki Shime; Ayako Kojima; Akira Maruyama; Yusuke Saito; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  J Innate Immun       Date:  2013-10-29       Impact factor: 7.349

Review 6.  Necroptosis, in vivo detection in experimental disease models.

Authors:  Sandrine Jouan-Lanhouet; Franck Riquet; Linde Duprez; Tom Vanden Berghe; Nozomi Takahashi; Peter Vandenabeele
Journal:  Semin Cell Dev Biol       Date:  2014-08-23       Impact factor: 7.727

7.  TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosis.

Authors:  Tsukasa Seya; Hiroaki Shime; Hiromi Takaki; Masahiro Azuma; Hiroyuki Oshiumi; Misako Matsumoto
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

8.  Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

9.  Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells.

Authors:  Masahiro Azuma; Takashi Ebihara; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110
  9 in total
  5 in total

Review 1.  Targeting innate sensing in the tumor microenvironment to improve immunotherapy.

Authors:  Zhida Liu; Chuanhui Han; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2019-12-16       Impact factor: 11.530

Review 2.  The Role of Toll-Like Receptor in Inflammation and Tumor Immunity.

Authors:  Xiaohong Cen; Shuwen Liu; Kui Cheng
Journal:  Front Pharmacol       Date:  2018-08-06       Impact factor: 5.810

Review 3.  RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review).

Authors:  Yuping Liu; Ting Liu; Tiantian Lei; Dingding Zhang; Suya Du; Lea Girani; Dandan Qi; Chen Lin; Rongsheng Tong; Yi Wang
Journal:  Int J Mol Med       Date:  2019-06-14       Impact factor: 4.101

4.  ABIN-1 is a key regulator in RIPK1-dependent apoptosis (RDA) and necroptosis, and ABIN-1 deficiency potentiates necroptosis-based cancer therapy in colorectal cancer.

Authors:  Jiali Cai; Die Hu; Judy Sakya; Tao Sun; Daoyong Wang; Lin Wang; Xiaohua Mao; Zhenyi Su
Journal:  Cell Death Dis       Date:  2021-02-01       Impact factor: 8.469

5.  Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification.

Authors:  Kai Sun; Jing-Zhang Li; Zhan-Xiong Luo; Cheng Huang
Journal:  World J Surg Oncol       Date:  2022-10-17       Impact factor: 3.253
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.